Clinical and radiological regression of cerebral and spinal metastases of a BRAF V600-mutated malignant melanoma after a single dose of ipilimumab/nivolumab followed by BRAF/MEK inhibition

Yervoy (ipilimumab) - BMS

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Laura Susok; Thilo Gambichler; Pia Ducker; Sera Selina Weyer-Fahlbusch

Sep 7, 2026